$2.53T
Total marketcap
$189.93B
Total volume
BTC 50.01%     ETH 15.90%
Dominance

Sage Therapeutics SAGE Stock

19.37 USD {{ price }} -3.004499% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
1.16B USD
LOW - HIGH [24H]
18.96 - 19.96 USD
VOLUME [24H]
1.19M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-9.05 USD

Sage Therapeutics Price Chart

Sage Therapeutics SAGE Financial and Trading Overview

Sage Therapeutics stock price 19.37 USD
Previous Close 58.04 USD
Open 57.94 USD
Bid 0 USD x 900
Ask 0 USD x 800
Day's Range 55.98 - 58.03 USD
52 Week Range 31.42 - 59.99 USD
Volume 750.09K USD
Avg. Volume 513.53K USD
Market Cap 3.35B USD
Beta (5Y Monthly) 1.155281
PE Ratio (TTM) N/A
EPS (TTM) -9.05 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 61.59 USD

SAGE Valuation Measures

Enterprise Value 2.35B USD
Trailing P/E N/A
Forward P/E -6.500579
PEG Ratio (5 yr expected) -0.18
Price/Sales (ttm) 356.7412
Price/Book (mrq) 2.9587045
Enterprise Value/Revenue 249.995
Enterprise Value/EBITDA -4.064

Trading Information

Sage Therapeutics Stock Price History

Beta (5Y Monthly) 1.155281
52-Week Change 65.68%
S&P500 52-Week Change 20.43%
52 Week High 59.99 USD
52 Week Low 31.42 USD
50-Day Moving Average 49.91 USD
200-Day Moving Average 42.83 USD

SAGE Share Statistics

Avg. Volume (3 month) 513.53K USD
Avg. Daily Volume (10-Days) 645.93K USD
Shares Outstanding 59.76M
Float 52.26M
Short Ratio 10.35
% Held by Insiders 12.49%
% Held by Institutions 88.82%
Shares Short 5.41M
Short % of Float 11.83%
Short % of Shares Outstanding 9.05%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -6163.65%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -24.74%
Return on Equity (ttm) -40.52%

Income Statement

Revenue (ttm) 9.4M USD
Revenue Per Share (ttm) 0.16 USD
Quarterly Revenue Growth (yoy) 108.20%
Gross Profit (ttm) -319290000 USD
EBITDA -578089984 USD
Net Income Avi to Common (ttm) -557556992 USD
Diluted EPS (ttm) -9.43
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.13B USD
Total Cash Per Share (mrq) 18.9 USD
Total Debt (mrq) 10.45M USD
Total Debt/Equity (mrq) 0.92 USD
Current Ratio (mrq) 14.21
Book Value Per Share (mrq) 18.961

Cash Flow Statement

Operating Cash Flow (ttm) -505918016 USD
Levered Free Cash Flow (ttm) -308794496 USD

Profile of Sage Therapeutics

Country United States
State MA
City Cambridge
Address 215 First Street
ZIP 02142
Phone 617 299 8380
Website https://www.sagerx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 689

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Q&A For Sage Therapeutics Stock

What is a current SAGE stock price?

Sage Therapeutics SAGE stock price today per share is 19.37 USD.

How to purchase Sage Therapeutics stock?

You can buy SAGE shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Sage Therapeutics?

The stock symbol or ticker of Sage Therapeutics is SAGE.

Which industry does the Sage Therapeutics company belong to?

The Sage Therapeutics industry is Biotechnology.

How many shares does Sage Therapeutics have in circulation?

The max supply of Sage Therapeutics shares is 60.11M.

What is Sage Therapeutics Price to Earnings Ratio (PE Ratio)?

Sage Therapeutics PE Ratio is now.

What was Sage Therapeutics earnings per share over the trailing 12 months (TTM)?

Sage Therapeutics EPS is -9.05 USD over the trailing 12 months.

Which sector does the Sage Therapeutics company belong to?

The Sage Therapeutics sector is Healthcare.

Sage Therapeutics SAGE included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Global Market Composite NQGM 2185.85 USD
-0.31
2177.48 USD 2204.21 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD